Tuesday, June 23, 2015. An article published online on March 20, 2015 in the International Journal of Physiology, Pathophysiology and Pharmacology reveals a benefit for pretreatment with coenzyme Q10 (CoQ10) in rats in which myocardial infarction (MI, or heart attack) was experimentally induced.
The study involved groups of rats that underwent sham surgery, no surgery, experimental MI alone, or experimental MI that followed a week of treatment with resveratrol, CoQ10 or both compounds. Infarct area, hemodynamic factors, inflammation and markers of oxidative stress were assessed 24 hours following the surgery.
Among animals that received CoQ10 alone or in combination with resveratrol, left ventricular infarct area was significantly reduced and left ventricular hemodynamic parameters were normalized. Serum brain natriuretic peptide, which can be elevated in heart failure, and markers of inflammation, including tumor necrosis factor-alpha (TNF-a) and interleukin-6 (IL-6), were also lower among animals pretreated with CoQ10. While thiobarbituric acid reactive substances (a byproduct of lipid peroxidation) were lower in CoQ10-treated animals, indicating decreased oxidative stress, the endogenous antioxidants superoxide dismutase (SOD) and glutathione peroxidase were found to have increased.
"The mechanism of the cardioprotective action of CoQ10 involved blocking exaggerated oxidative stress and inflammation post MI, resulting in normalized/optimized hemodynamics and reduced infarct area of the left ventricle," write Mahmoud Alkhateeb of King Khalid University and colleagues. "The mechanism of the cardioprotective action of CoQ10 involved blocking exaggerated oxidative stress and inflammation post MI, resulting in normalized/optimized hemodynamics and reduced infarct area of the left ventri-cle," write authors Samy M. Eleawa and colleagues. "DNA damage to the heart following MI was likely also reduced with CoQ10, as supported by reduced Bax and p53 gene expression in the left ventricle."
"We propose that CoQ10 is an effective antioxidant/anti-inflammatory agent to combat against acute cardiac changes induced by MI and can be an attractive therapeutic option in patients undergoing cardiac changes post MI," they conclude.